Celldx provides deep genomic analysis for patients with advanced cancer. It helps in the evaluation of companion diagnostic therapies across several cancer indications, and clinical trial matching across all solid tumors. 

It also helps inform immunotherapy decisions by including genomic signatures such as microsatelllite instability (MSI), tumor mutational burden (TMB) and PDL1 status.